Status and phase
Conditions
Treatments
About
A multicenter, randomized, controlled, single blind clinical trial on the efficacy and safety of esmketamine injection in electroconvulsive therapy
Objective to evaluate the efficacy and safety of esmketamine injection in the treatment of non convulsive electroconvulsive therapy
Participants: Patients with depression receiving MECT
The research drug was esketamine injection
The study design was a multicenter, randomized, single blind, parallel controlled trial
25 mg / kg as the experimental group. The normal saline group was the control group (0.05 ml / kg).
The sample size was estimated according to the main efficacy index (remission rate) of this study. It was assumed that the remission rate of the esketamine injection group was better than that of the control group. The parameters were set as test level α = 0.05, unilateral, β = 0.8, the cut-off value was 6%, the experimental group: the control group was 1:1, according to the results of previous clinical trials and combined with literature, the remission rate of the control group was 69%, 159 cases in each group, considering the 20% shedding rate, 198 cases in the experimental group and 198 cases in the control group were selected.
experimental group
The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy
In the control group
The patients were given 0.05ml/kg of normal saline, 1.5mg/kg of propofol and 1mg / kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy
Efficacy evaluation 1. Main efficacy indicators
Remission rate of depressive symptoms after MECT treatment
Remission was defined as two consecutive hdrs-24 scores ≤ 10 after receiving MECT
Definition rate of remission rate: the proportion of patients with remission of depressive symptoms in this group
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
396 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal